Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5841632 | Life Sciences | 2015 | 7 Pages |
Abstract
Our study demonstrates that reduced hepatic Ugt1a activity during obesity likely contributes to reduced glucuronidation, and results in higher levels of the toxic metabolite, SN-38. Thus, irinotecan dosage should be closely monitored for effective and safe chemotherapy in obese cancer patients who are at a higher risk of developing liver toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Pankajini Mallick, Pranav Shah, Adarsh Gandhi, Romi Ghose,